vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and NATIONAL BANKSHARES INC (NKSH). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $15.3M, roughly 1.2× NATIONAL BANKSHARES INC). NATIONAL BANKSHARES INC runs the higher net margin — 38.5% vs -64.1%, a 102.6% gap on every dollar of revenue. On growth, NATIONAL BANKSHARES INC posted the faster year-over-year revenue change (24.7% vs 9.8%). NATIONAL BANKSHARES INC produced more free cash flow last quarter ($15.2M vs $-11.8M). Over the past eight quarters, NATIONAL BANKSHARES INC's revenue compounded faster (20.9% CAGR vs 4.5%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
ENTA vs NKSH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $15.3M |
| Net Profit | $-11.9M | $5.9M |
| Gross Margin | — | — |
| Operating Margin | -60.5% | 47.4% |
| Net Margin | -64.1% | 38.5% |
| Revenue YoY | 9.8% | 24.7% |
| Net Profit YoY | 46.4% | 91.0% |
| EPS (diluted) | $-0.42 | $0.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $15.3M | ||
| Q3 25 | $15.1M | $14.2M | ||
| Q2 25 | $18.3M | $13.3M | ||
| Q1 25 | $14.9M | $12.8M | ||
| Q4 24 | $17.0M | $12.2M | ||
| Q3 24 | $14.6M | $11.7M | ||
| Q2 24 | $18.0M | $10.9M | ||
| Q1 24 | $17.1M | $10.4M |
| Q4 25 | $-11.9M | $5.9M | ||
| Q3 25 | $-18.7M | $4.4M | ||
| Q2 25 | $-18.3M | $2.3M | ||
| Q1 25 | $-22.6M | $3.2M | ||
| Q4 24 | $-22.3M | $3.1M | ||
| Q3 24 | $-28.8M | $2.7M | ||
| Q2 24 | $-22.7M | $-307.0K | ||
| Q1 24 | $-31.2M | $2.2M |
| Q4 25 | -60.5% | 47.4% | ||
| Q3 25 | -121.6% | 37.9% | ||
| Q2 25 | -103.2% | 20.0% | ||
| Q1 25 | -164.3% | 30.5% | ||
| Q4 24 | -138.8% | 30.1% | ||
| Q3 24 | -204.4% | 27.5% | ||
| Q2 24 | -134.6% | -4.4% | ||
| Q1 24 | -192.1% | 25.8% |
| Q4 25 | -64.1% | 38.5% | ||
| Q3 25 | -123.6% | 31.1% | ||
| Q2 25 | -99.7% | 17.2% | ||
| Q1 25 | -151.7% | 25.3% | ||
| Q4 24 | -131.4% | 25.1% | ||
| Q3 24 | -197.3% | 22.8% | ||
| Q2 24 | -126.1% | -2.8% | ||
| Q1 24 | -182.7% | 20.8% |
| Q4 25 | $-0.42 | $0.93 | ||
| Q3 25 | $-0.88 | $0.69 | ||
| Q2 25 | $-0.85 | $0.36 | ||
| Q1 25 | $-1.06 | $0.51 | ||
| Q4 24 | $-1.05 | $0.50 | ||
| Q3 24 | $-1.36 | $0.42 | ||
| Q2 24 | $-1.07 | $-0.05 | ||
| Q1 24 | $-1.47 | $0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $59.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $184.9M |
| Total Assets | $329.5M | $1.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | $59.3M | ||
| Q3 25 | $32.3M | $42.3M | ||
| Q2 25 | $44.8M | $92.8M | ||
| Q1 25 | $60.2M | $122.5M | ||
| Q4 24 | $84.3M | $108.1M | ||
| Q3 24 | $37.2M | $49.8M | ||
| Q2 24 | $35.8M | $98.9M | ||
| Q1 24 | $63.5M | $121.2M |
| Q4 25 | $126.6M | $184.9M | ||
| Q3 25 | $64.7M | $179.2M | ||
| Q2 25 | $79.3M | $168.7M | ||
| Q1 25 | $93.5M | $167.3M | ||
| Q4 24 | $111.8M | $156.4M | ||
| Q3 24 | $128.8M | $167.8M | ||
| Q2 24 | $148.9M | $149.0M | ||
| Q1 24 | $166.1M | $139.4M |
| Q4 25 | $329.5M | $1.8B | ||
| Q3 25 | $280.7M | $1.8B | ||
| Q2 25 | $301.0M | $1.8B | ||
| Q1 25 | $323.0M | $1.8B | ||
| Q4 24 | $348.6M | $1.8B | ||
| Q3 24 | $376.7M | $1.8B | ||
| Q2 24 | $398.8M | $1.8B | ||
| Q1 24 | $413.6M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $17.9M |
| Free Cash FlowOCF − Capex | $-11.8M | $15.2M |
| FCF MarginFCF / Revenue | -63.6% | 99.2% |
| Capex IntensityCapex / Revenue | 0.8% | 17.9% |
| Cash ConversionOCF / Net Profit | — | 3.04× |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | $23.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $17.9M | ||
| Q3 25 | $-6.5M | $6.1M | ||
| Q2 25 | $17.5M | $2.1M | ||
| Q1 25 | $-13.5M | $2.6M | ||
| Q4 24 | $-16.8M | $9.4M | ||
| Q3 24 | $-10.4M | $3.1M | ||
| Q2 24 | $-14.8M | $-3.0M | ||
| Q1 24 | $-28.6M | $3.8M |
| Q4 25 | $-11.8M | $15.2M | ||
| Q3 25 | $-7.9M | $5.3M | ||
| Q2 25 | $17.4M | $1.5M | ||
| Q1 25 | $-16.0M | $1.6M | ||
| Q4 24 | $-25.5M | $6.2M | ||
| Q3 24 | $-19.4M | $2.2M | ||
| Q2 24 | $-21.3M | $-4.0M | ||
| Q1 24 | $-30.3M | $3.5M |
| Q4 25 | -63.6% | 99.2% | ||
| Q3 25 | -52.5% | 37.4% | ||
| Q2 25 | 94.7% | 11.5% | ||
| Q1 25 | -107.4% | 12.5% | ||
| Q4 24 | -150.6% | 50.5% | ||
| Q3 24 | -132.5% | 18.5% | ||
| Q2 24 | -118.6% | -36.3% | ||
| Q1 24 | -177.5% | 33.8% |
| Q4 25 | 0.8% | 17.9% | ||
| Q3 25 | 9.6% | 5.6% | ||
| Q2 25 | 0.8% | 4.1% | ||
| Q1 25 | 17.0% | 7.5% | ||
| Q4 24 | 51.6% | 26.6% | ||
| Q3 24 | 61.3% | 8.3% | ||
| Q2 24 | 36.4% | 9.3% | ||
| Q1 24 | 9.8% | 3.0% |
| Q4 25 | — | 3.04× | ||
| Q3 25 | — | 1.38× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.79× | ||
| Q4 24 | — | 3.07× | ||
| Q3 24 | — | 1.17× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
